Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the ...

Fatigue, bone pain, and frequent infections can all be signs of the blood cancer multiple myeloma, which often has no early distinctive symptoms.

Multiple myeloma bone lesions occur when cancerous cells cause the bones to form weak spots, which can lead to breaks. Learn more about lesions and pain.

Kyphoplasty is being used to treat painful osteolytic or fractured vertebrae, but will it become a key treatment option for patients with vertebral osteolyses from multiple myeloma?

The clinical presentation of multiple myeloma varies widely. Some patients are asymptomatic, with the disease discovered through routine blood tests, while others present with severe symptoms such as ...

JERSEY CITY, NJ, USA I July 7, 2025 I Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in ...

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term outcomes thwarted by repeated cycles of relapse and remission.

Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while ...

The EMA has extended the indications for Darzalex (daratumumab) to the treatment of adults at high risk of developing multiple myeloma.

In spite of recent advances in the management of multiple myeloma, cure has been elusive, with efforts to improve long-term ...